Physician profile
David L Sneed
NPI 1134113137
$2,197.07
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $402 · 2021: $308 · 2022: $264 · 2024: $87.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $655.39 | 2019-2022 | |
| Abbvie INC. | $228.17 | 2019-2024 | |
| Antares Pharma, INC. | $218.45 | 2019-2022 | |
| Galderma Laboratories, L.P. | $165.98 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $157.33 | 2019 | |
| Lilly USA, LLC | $133.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.68 | 2019-2020 | |
| Amarin Pharma, INC. | $86.95 | 2019-2020 | |
| Amgen INC. | $72.89 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $61.89 | 2019 | |
| Shire North American Group INC | $52.67 | 2019 | |
| Althera Pharmaceuticals LLC | $46.21 | 2021 | |
| Ibsa Pharma INC. | $35.95 | 2019 | |
| Aytu Biopharma, INC. | $32.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.53 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $24.10 | 2019 | |
| Redhill Biopharma INC. | $20.37 | 2020 | |
| Adlon Therapeutics L.P. | $18.42 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.95 | 2019 | |
| Novo Nordisk INC | $16.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sneed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.